City Therapeutics files for US IPO as biotech listings surge

City Therapeutics has filed for a US initial public offering (IPO) on Thursday, joining a surge of biotech firms seeking to list shares ahead of the fall IPO window. Biotechnology has been a major focus of the IPO market this year, with strong investor interest in the sector. However, fall listings have faced challenges due to rising bond yields, tighter credit conditions, and concerns surrounding the AI trade, which have dampened market sentiment.

For biotech companies with promising therapeutic candidates, minor changes in interest rates or macroeconomic headwinds do not significantly impact their prospects. According to Matt Kennedy, a senior strategist at Renaissance Capital, the primary factors determining a biotech's success are the efficacy of its drug candidates in clinical trials and overall biotech sentiment, which remains robust despite headwinds in the broader IPO market.

Other biotech firms, including Retension Pharmaceuticals, TRex Bio, and Iambic Therapeutics, have also recently filed for US IPOs, marking a significant milestone in their development journey. ADARx Pharmaceuticals, which focuses on developing RNA-based drugs for rare diseases, is set to go public on Friday.

Founded in 2023, City Therapeutics is advancing a pipeline of RNA-based drugs targeting rare diseases. Its most advanced product candidate, CITY-FXI, is currently in an early-stage trial aimed at treating thrombosis – the formation of harmful blood clots within blood vessels. Based in Cambridge, Massachusetts, the company has raised approximately $238.8 million since its inception from various life sciences investors, such as ARCH Venture Partners, Fidelity Management & Research Company, Invus, and Viking Global Investors.

In addition to clinical advancements, IPO investors are also evaluating the potential for partnerships with major pharmaceutical companies. Such collaborations could enhance the likelihood of subsequent acquisitions, as they can provide access to larger distribution networks and resources. The underwriters for City Therapeutics' offering include Goldman Sachs, Jefferies, Stifel, and Oppenheimer, and the company will be listed on the Nasdaq under the ticker symbol CTY.